SLC5A2 and heart failure: As the SGLT2 inhibitor arm was superior to the placebo in terms of heart failure hospitalization and cardiovascular death in landmark clinical trials, it is intriguing to note that significant differences between users of dapagliflozin and empagliflozin were observed only for these two outcomes [2–4, 12–17].